Document Detail

Targeting the epidermal growth factor receptor in solid tumor malignancies.
MedLine Citation:
PMID:  22385404     Owner:  NLM     Status:  In-Data-Review    
The epidermal growth factor receptor (EGFR) is over-expressed, as well as mutated, in many types of cancers. In particular, the EGFR variant type III mutant (EGFRvIII) has attracted much attention as it is frequently and exclusively found on many tumor cells, and hence both EGFR and EGFRvIII have been proposed as valid targets in many cancer therapy settings. Different strategies have been developed in order to either inhibit EGFR/EGFRvIII activity or to ablate EGFR/EGFRvIII-positive tumor cells. Drugs that inhibit these receptors include monoclonal antibodies (mAbs) that bind to the extracellular part of EGFR, blocking the binding sites for the EGFR ligands, and intracellular tyrosine kinase inhibitors (TKIs) that block the ATP binding site of the tyrosine kinase domain. Besides an EGFRvIII-targeted vaccine, conjugated anti-EGFR mAbs have been used in different settings to deliver lethal agents to the EGFR/EGFRvIII-positive cells; among these are radio-labelled mAbs and immunotoxins. This article reviews the current status and efficacy of EGFR/EGFRvIII-targeted therapies.
Mette K Nedergaard; Chris J Hedegaard; Hans S Poulsen
Related Documents :
22482734 - Aptamer-enabled efficient isolation of cancer cells from whole blood using a microfluid...
9469424 - Bispecific molecules directed to the fc receptor for iga (fc alpha ri, cd89) and tumor ...
3493084 - Activation of the il-1 pathway during amplification of immune responses in tumor-bearin...
17579054 - Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis ind...
18521084 - E2f-1 transcriptional activity is a critical determinant of mdm2 antagonist-induced apo...
2437064 - Raised serum alpha-fetoprotein in sertoli-leydig cell tumor (androblastoma) of ovary: r...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy     Volume:  26     ISSN:  1173-8804     ISO Abbreviation:  BioDrugs     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9705305     Medline TA:  BioDrugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  83-99     Citation Subset:  IM    
Department of Radiation Biology, the Finsencenter, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
Next Document:  Hyaluronic Acid for the Treatment of Osteoarthritis in all Joints Except the Knee: What is the Curre...